EWTX
Edgewise Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$38.81-2.39%
Price as of Jul 20, 2026
EWTX growth
Edgewise Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -8.3%
- EBIT
- -17.4%
- EPS
- -7.1%
- Free cash flow
- -24.6%
- Operating cash flow
- -25.5%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -30.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -25.9%
- EBIT
- -20.5%
- Net income
- -25.4%
- EPS
- -12.4%
- Free cash flow
- -30.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.